Cryoport, Inc. (NASDAQ:CYRX) Insider Sells $23,977.18 in Stock

Cryoport, Inc. (NASDAQ:CYRX) insider Mark W. Sawicki sold 1,367 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $17.54, for a total value of $23,977.18. Following the completion of the transaction, the insider now owns 77,444 shares in the company, valued at approximately $1,358,367.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Cryoport Stock Performance

Shares of CYRX stock opened at $17.70 on Friday. The business’s 50-day moving average price is $16.02 and its 200-day moving average price is $14.40. Cryoport, Inc. has a 12 month low of $9.00 and a 12 month high of $24.30. The firm has a market capitalization of $866.95 million, a price-to-earnings ratio of -8.05 and a beta of 1.61. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82.

Analysts Set New Price Targets

A number of brokerages recently commented on CYRX. UBS Group raised their price target on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, March 15th. Stephens restated an “equal weight” rating and issued a $17.00 price target on shares of Cryoport in a research report on Wednesday, March 13th. Finally, Needham & Company LLC reduced their price objective on Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Cryoport presently has an average rating of “Hold” and an average target price of $18.29.

Institutional Trading of Cryoport

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its stake in shares of Cryoport by 228.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock valued at $36,000 after purchasing an additional 1,433 shares in the last quarter. Quarry LP acquired a new position in shares of Cryoport in the second quarter worth approximately $40,000. Captrust Financial Advisors lifted its stake in shares of Cryoport by 308.3% in the second quarter. Captrust Financial Advisors now owns 2,319 shares of the company’s stock worth $72,000 after acquiring an additional 1,751 shares during the period. FMR LLC lifted its stake in shares of Cryoport by 34.1% in the first quarter. FMR LLC now owns 2,935 shares of the company’s stock worth $70,000 after acquiring an additional 747 shares during the period. Finally, State of Wyoming lifted its stake in shares of Cryoport by 42.7% in the fourth quarter. State of Wyoming now owns 3,026 shares of the company’s stock worth $53,000 after acquiring an additional 905 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.